Neuren Pharmaceuticals Limited (ASX:NEU)
Australia · Delayed Price · Currency is AUD | Market Cap | 2.21B +25.1% |
| Revenue (ttm) | 64.65M -70.2% |
| Net Income | 30.44M -78.6% |
| EPS | 0.23 -78.6% |
| Shares Out | 126.32M |
| PE Ratio | 75.25 |
| Forward PE | 61.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 338,151 |
| Open | 17.49 |
| Previous Close | 17.54 |
| Day's Range | 17.19 - 17.65 |
| 52-Week Range | 11.00 - 22.99 |
| Beta | 1.62 |
| Analysts | Strong Buy |
| Price Target | 24.33 (+38.95%) |
| Earnings Date | Aug 28, 2026 |
About Neuren Pharmaceuticals
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develo... [Read more]
Financial Performance
In 2025, Neuren Pharmaceuticals's revenue was 64.65 million, a decrease of -70.18% compared to the previous year's 216.83 million. Earnings were 30.44 million, a decrease of -78.57%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for NEU stock is "Strong Buy." The 12-month stock price target is $24.33, which is an increase of 38.95% from the latest price.
News
ASX 200 Ends Flat at 8,820 After Volatile Day, Even as Neuren Pharmaceuticals Stuns With 36% Surge
The ASX 200 closed nearly unchanged, buoyed by a biotech surge and easing geopolitical tensions, while investors await Chinese manufacturing data and Reserve Bank policy updates.
Neuren Pharmaceuticals Shares Surge 36% on Positive European Opinion for Rett Syndrome Drug
Neuren Pharmaceuticals' shares rose 36% after its Rett syndrome drug received a positive EU recommendation, marking a significant milestone for the rare disease treatment.
Neuren Pharmaceuticals Transcript: AGM 2026
Strong financial growth driven by DAYBUE royalties and expanding U.S. market presence was highlighted, with strategic focus on advancing NNZ-2591 clinical trials and exploring new indications. Dividend policy and capital management remain under review, while regulatory and market challenges were openly discussed.
Neuren Pharmaceuticals Annual report: H2 2025
Neuren Pharmaceuticals has published its H2 2025 annual report on February 27, 2026.
Neuren Pharmaceuticals Earnings release: H2 2025
Neuren Pharmaceuticals released its H2 2025 earnings on February 27, 2026, summarizing the period's financial results.
Neuren Pharmaceuticals Transcript: Investor update
A new share buyback of up to 5% was approved, reflecting strong financials and confidence in future growth. Key clinical programs for PMS, Pitt Hopkins, and HIE are prioritized, with PMS phase III now underway and additional studies targeted for late 2024. Management remains focused on orphan indications and sees recent share price volatility as disconnected from fundamentals.
Neuren Pharmaceuticals Press release: Investor update
Neuren Pharmaceuticals issued a press release on February 11, 2026, disclosing material business information to investors.
Neuren Pharmaceuticals Slides: Investor Presentation
Neuren Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on November 9, 2025.
Neuren Pharmaceuticals Quarterly report: H1 2025
Neuren Pharmaceuticals has published its H1 2025 quarterly earnings report on August 27, 2025.
Neuren Pharmaceuticals Earnings release: H1 2025
Neuren Pharmaceuticals released its H1 2025 earnings on August 27, 2025, summarizing the period's financial results.
Neuren Pharmaceuticals Slides: Investor Presentation
Neuren Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 26, 2025.
Neuren Pharmaceuticals upgraded to Buy from Hold at Jefferies
Jefferies analyst David Stanton upgraded Neuren Pharmaceuticals to Buy from Hold with a price target of A$16.75, up from A$11.20. Acadia acquired ex-North American rights to trofinetide and global rig...